Light and challenges: Advances in targeted therapy for glioma
Journal Title: Chinese Journal of Nervous and Mental Diseases - Year 2025, Vol 51, Issue 1
Abstract
Glioma is the most common malignant primary brain tumor in adults, characterized by rapid malignant progression, high recurrence rates, and high mortality. The main treatment methods are surgery followed by radiotherapy and chemotherapy. Temozolomide, as the first-line drug for glioma treatment, is exposed to increasingly severe issues with drug resistance, which significantly impacts the efficacy and prognosis for glioma patients. With advancements in molecular biomarker detection and the emergence of precision medicine, targeted and individualized treatment strategies for glioma patients are evolving rapidly. The discovery of new glioma biomarkers, such as long non-coding RNA HOTAIR (HOX antisense intergenic RNA), polymerase I and transcript release factor (PTRF/Cavin1), and MET, along with the application of new technologies like computer-aided drug design (CADD), has ushered in a new era for the design and development of targeted drugs for glioma. Due to the heterogeneity of glioma, the effectiveness of single-target drugs is limited. In the future, a combination of physical, chemical, and biological interventions will be the breakthrough direction for glioma treatment.
Authors and Affiliations
Dongyuan SU, Chunsheng. KANG
Keywords
Related Articles
- EP ID EP762093
- DOI 10.3969/j.issn.1002-0152.2025.01.001
- Views 26
- Downloads 0
Research progress on autoimmune glial fibrillary acidic protein astrocytopathy
Autoimmune glial fibrillary acidic protein astropathy (GFAP-A) is an autoimmune inflammatory disease of the central nervous system, with a prevalence rate of 0.6 per 100,000. Its clinical manifestations include subacute...
Progress of long chain non-coding RNAs in the inflammatory response to cerebral ischemia-reperfusion injury
Inflammatory response is one of the key mechanisms of cerebral ischemia/reperfusion injury (CIRI), which seriously affects the prognosis of patients. In recent years, it has been found that long non-coding RNA (LncRNA) i...
The clinical value of visual evoked potential in assessing visual pathway of visual hallucinations in Parkinson disease
[Objective] This research was to evaluate the integrity of visual pathways in patients with Parkinson disease (PD) by visual evoked potential (VEP), especially those with visual hallucinations. [Methods] A total of 76 PD...
Research progress of neuropsychiatric disorder in pituitary neuroendocrine tumor
This article seeks to delve into the correlation between pituitary neuroendocrine tumors (PitNET) and neuropsychiatric disorders while summarizing the most recent advancements in related research. Some patients with PitN...
Research status of non-drug treatment of vestibular migraine
Due to the limitations of drug treatment of vestibular migraine VM,the exploration of non-drug treatment is particularly important. In recent years,the research on non-drug treatment of VM mainly focuses on four aspects:...